Medicine Overview
Adult Dose
| Clinical Information | Administration Information |
|---|---|
|
Indication: Philadelphia chromosome-positive (Ph+) Acute Lymphoblastic Leukemia (ALL) Age: Adults Condition: Resistance or intolerance to prior therapy |
Dose: Oral – 140 mg Frequency: once daily Note: Initial dosage. May increase to 180 mg once daily if hematologic or cytogenetic response not achieved with initial dosage. |
|
Indication: Chronic Myeloid Leukemia (CML) Condition: Newly diagnosed in chronic phase |
Dose: Oral – 100 mg Frequency: once daily Note: May increase to 140 mg orally once daily if hematologic or cytogenetic response not achieved with initial dosage. Therapy was continued until disease progression or until no longer tolerated in clinical studies. |
Child Dose
| Clinical Information | Administration Information |
|---|---|
|
Indication: Acute Lymphoblastic Leukemia Age: greater than 1 years |
Dose: Tablet – Not recommended Note: Begin therapy on or before day 15 of induction chemotherapy; Continue therapy for 2 years |
|
Indication: Acute Lymphoblastic Leukemia Age: greater than 1 years |
Dose: Tablet – 40 mg Frequency: once daily Duration: 2 years Note: by mouth (oral); Begin therapy on or before day 15 of induction chemotherapy |
Renal Dose
| Clinical Information | Administration Information |
|---|---|
|
Condition: Renal impairment |
Dose: Not specified Note: No significant impact on pharmacokinetics |
Administration
- Can be taken with or without food
- Swallow whole tablet
Side Effect
- Fluid retention, incl CHF
- pulm edema
- pleural effusion (50%)
- Diarrhea (49%)
- Headache (40%)
- Hemorrhage (40%)
- Fatigue (39%)
- Pyrexia (39%)
- Skin rash (35%)
- Infection (34%)
- Nausea (34%)
- Dyspnea (32%)
- Cough (28%)
- Pain (26%)
- Abdominal pain (25%)
- Vomiting (22%)
- Anorexia (19%)
- Arthralgia (19%)
- Asthenia (19%)
- Constipation (14%)
- Dizziness (14%)
- Musculoskeletal pain (14%)
- Weight loss (14%)
- Chest pain (13%)
- Neuropathy (13%)
- Myalgia (12%)
- Abdominal distention (11%)
- Arrhythmia (11%)
- Chills (11%)
- Pneumonia (11%)
- Pruritus (11%)
- Weight gain (11%)
- Anemia
- Febrile neutropenia
- Thrombocytopenia
- Mucosal inflammation
- Thrombosis/embolism (including pulmonary embolism, Deep vein thrombosis (DVT))
- thoracic and mediastinal disorders Interstitial lung disease
- pulmonary arterial hypertension
- Stevens-Johnson syndrome
- erythema multiforme
Drug Interaction
Drug Interaction
| Drug Name | Risk Factors |
|---|---|
|
Alfentanil, cisapride, ciclosporin, fentanyl, pimozide, quinidine, simvastatin, sirolimus, tacrolimus, ergot alkaloids
|
May increase serum levels of these drugs
|
|
Antiplatelet drugs, Anticoagulants (Warfarin, Heparin, Dabigatran, Rivaroxaban, Apixaban, Edoxaban), NSAIDs (Ibuprofen, Naproxen, Diclofenac, Celecoxib, Meloxicam, Indomethacin, Piroxicam, Ketorolac)
|
Increased risk of bleeding and thrombocytopenia
|
Disease Interaction
Disease Interaction
| Disease Name | Risk Factors |
|---|---|
|
Concurrent CYP3A4 Inhibitor Use
|
Risk of drug interactions
|
|
Pregnancy
|
Risk of fetal harm
|
Pregnancy
Pregnancy
Lactation
Special Use
Precaution
Overdose
Pharmacology
Storage
Dasatinib tablets should be stored at 20°C to 25°C
Data Sources
Clinical & regulatory information on this page is compiled from the following government sources:
DISCLAIMER: This drug information content is provided for informational purposes only and is not intended to be a substitute for professional medical advice, diagnosis, or treatment. Patients should always consult their physician with any questions regarding a medical condition and to obtain medical advice and treatment.